Key clinical point: Nilotinib is safe and tolerable in patients with moderate or advanced Parkinson’s disease.
Major finding: One treatment-related serious adverse event occurred; the patient was in the 300-mg/day group.
Study details: A randomized, double-blind, placebo-controlled, parallel-group study of nilotinib in 76 patients with Parkinson’s disease.
Disclosures: The Michael J. Fox Foundation, the Cure Parkinson’s Trust, and Van Andel Research Institute funded the study. Novartis provided the study drug and placebo. The investigators reported no conflicts of interest.
Simuni T et al. AAN 2020. Abstract 43617.